Exhibit (a)(1)(SS)


                            [LETTERHEAD OF OMNICARE]
Omnicare                                                            news release
--------------------------------------------------------------------------------

           Omnicare Issues Statement On Delaware Chancery Court Ruling
                       In NCS Stockholder-Plaintiffs Case


COVINGTON, Ky, November 25, 2002 - Omnicare, Inc. (NYSE: OCR), a leading
provider of pharmaceutical care for the elderly, today released the following
statement concerning the decision issued on Friday, November 22, 2002, by the
Delaware Chancery Court denying a motion brought by the NCS
stockholder-plaintiffs for a preliminary injunction seeking to enjoin the
acquisition of NCS HealthCare, Inc. (NCSS.OB) by Genesis Health Ventures, Inc.
(NASDAQ: GHVI).

         "The NCS stockholder-plaintiffs plan to seek an expedited appeal with
         respect to the Delaware Chancery Court's ruling.

         "Additionally, on November 14, 2002, Omnicare filed an appeal with the
         Delaware Supreme Court with respect to the Delaware Chancery Court's
         orders dismissing Omnicare's breach of fiduciary duty claims against
         the NCS directors for lack of standing, as well as entering summary
         judgment in favor of the defendants as to Omnicare's claim that Messrs.
         Outcalt's and Shaw's Class B common stock (ten votes per share)
         automatically converted to Class A common stock (one vote per share)
         upon execution of the voting agreements with Genesis.

         "Omnicare's appeal will be heard by the Delaware Supreme Court on
         December 3, 2002.

         "Omnicare remains fully committed to its superior offer to acquire NCS
         for $3.50 per share in cash. As of November 18, 2002, approximately 73
         percent of NCS's public stockholders tendered NCS shares into
         Omnicare's tender offer.

         "Significantly, the NCS Board of Directors recommends that NCS
         stockholders vote against the Genesis transaction."

Dewey Ballantine LLP is acting as legal counsel to Omnicare and Merrill Lynch is
acting as financial advisor. Innisfree M&A Incorporated is acting as Information
Agent.

                                     -more-






                                       -2-
About the Company
Omnicare, based in Covington, Kentucky, is a leading provider of pharmaceutical
care for the elderly. Omnicare serves approximately 746,000 residents in
long-term care facilities in 45 states, making it the nation's largest provider
of professional pharmacy, related consulting and data management services for
skilled nursing, assisted living and other institutional healthcare providers.
Omnicare also provides clinical research services for the pharmaceutical and
biotechnology industries in 28 countries worldwide. For more information, visit
the company's Web site at http://www.omnicare.com.

This document is neither an offer to purchase nor a solicitation of an offer to
sell securities. The tender offer is being made only through an offer to
purchase and related letter of transmittal. Investors and security holders are
strongly advised to read the tender offer statement of Omnicare because it
contains important information. The tender offer statement has been filed by
Omnicare with the Securities and Exchange Commission (SEC). Investors and
security holders may obtain a free copy of these statements (when available) and
other relevant documents on the SEC's Web site at: http://www.sec.gov. The
tender offer statement and related materials may also be obtained for free by
directing such requests to Omnicare at (859) 392-3331.

Statements in this press release concerning Omnicare's expectations regarding
the outcome of the litigation in Delaware Chancery Court and related appeals,
the relative value of Omnicare's offer, together with other statements that are
not historical, are forward-looking statements that are estimates reflecting the
best judgment of Omnicare based on currently available information. Such
forward-looking statements involve actual known and unknown risks,
uncertainties, contingencies and other factors that could cause actual results,
performance or achievements to differ materially from those stated. Such risks,
uncertainties, contingencies and other factors, many of which are beyond the
control of Omnicare, include overall economic, financial and business
conditions; trends for the continued growth of the businesses of Omnicare; the
ability to implement productivity, consolidation and cost reduction efforts and
to realize anticipated benefits; the impact and pace of pharmaceutical price
increases; delays and further reductions in governmental reimbursement to
customers and to Omnicare as a result of pressure on federal and state budgets
due to the continuing economic downturn and other factors; the overall financial
condition of Omnicare's customers; Omnicare's ability to assess and react to the
financial condition of its customers; the impact of seasonality on the business
of Omnicare; the ability of vendors to continue to provide products and services
to Omnicare; the continued successful integration of Omnicare's clinical
research business and acquired companies, including NCS, and the ability to
realize anticipated economies of scale and cost synergies; pricing and other
competitive factors in the industry; increases or decreases in reimbursement;
the effect of new government regulations, executive orders and/or legislative
initiatives, including those relating to reimbursement and drug pricing policies
and changes in the interpretation and application of such policies; government
budgetary pressures and shifting priorities; efforts by payors to control costs;
the outcome of litigation; the failure of Omnicare to obtain or maintain
required regulatory approvals or licenses; loss or delay of contracts pertaining
to Omnicare's contract research organization business for regulatory or other
reasons; the ability of clinical research projects to produce revenues in future
periods; the ability to attract and retain needed management; the impact and
pace of technological advances; the ability to obtain or maintain rights to
data, technology and other intellectual property; the impact of consolidation in
the pharmaceutical and long-term care industries; volatility in the market for
Omnicare's stock, the stock of Genesis Health Ventures, the stock of NCS and in
the financial markets generally; access to capital and financing; the demand for
Omnicare's products and services; variations in costs or expenses; the continued
availability of suitable acquisition candidates; changes in tax law and
regulation; changes in accounting rules and standards; and other risks and
uncertainties described in Omnicare's reports and filings with the Securities
and Exchange Commission.

                                       ###

Contacts:
Cheryl D. Hodges                          Joele Frank / Andy Brimmer
Omnicare, Inc.                            Joele Frank, Wilkinson Brimmer Katcher
(859) 392-3331                            (212) 355-4449, ext. 121